|Dr. Lakhmir S. Chawla||Consultant||560.21k||N/A||1971|
|Mr. Larry G. Edwards||Pres, CEO & Director||N/A||N/A||1972|
|Mr. Michael S. Hearne||CFO, Principal Financial & Accounting Officer||N/A||N/A||1963|
|Ms. Paula Rusu||VP of Operations||N/A||N/A||N/A|
|Ms. Sandra Vedrick||Sr. Director of Investor Relations & HR||N/A||N/A||N/A|
|Mr. Thomas Ouellette||VP of Sales & Marketing||N/A||N/A||N/A|
|Mr. Luke Seikkula||Sr. VP of Pharmaceutical Operations||N/A||N/A||1964|
|Mr. Stewart M. Kroll||Chief Devel. Officer||N/A||N/A||1959|
|Mr. Mark D. Williams||Sr. VP of Medical Affairs||N/A||N/A||N/A|
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.
La Jolla Pharmaceutical Company’s ISS Governance QualityScore as of December 2, 2020 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 2; Compensation: 9.